摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-bromo-1-((1-isopropyl-1H-pyrazol-3-yl)methyl)-4-nitro-1H-indazole | 1313410-21-7

中文名称
——
中文别名
——
英文名称
3-bromo-1-((1-isopropyl-1H-pyrazol-3-yl)methyl)-4-nitro-1H-indazole
英文别名
3-bromo-1-((1-isopropylpyrazole-3-yl)methyl)-4-nitro-1H-indazole;3-bromo-4-nitro-1-[(1-propan-2-ylpyrazol-3-yl)methyl]indazole
3-bromo-1-((1-isopropyl-1H-pyrazol-3-yl)methyl)-4-nitro-1H-indazole化学式
CAS
1313410-21-7
化学式
C14H14BrN5O2
mdl
——
分子量
364.201
InChiKey
KOWJXNOTCHMIRK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    81.5
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors
    申请人:Boys Mark Laurence
    公开号:US20120258952A1
    公开(公告)日:2012-10-11
    Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.
    公式(I)的化合物及其药学上可接受的盐,其中R1,R2,R3,R4和R5具有规范中给定的含义,是cFMS的抑制剂,并可用于治疗与骨相关的疾病、癌症、自身免疫性疾病、炎症性疾病、心血管疾病和疼痛。
  • SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    申请人:Boys Mark Laurence
    公开号:US20130274244A1
    公开(公告)日:2013-10-17
    Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    公式I的化合物及其药学上可接受的盐,其中R1、R2、R3、R4、R5和R6的含义如规范中所述,是cFMS的抑制剂,可用于治疗哺乳动物的纤维化、与骨有关的疾病、癌症、自身免疫性疾病、炎症性疾病、心血管疾病、疼痛和烧伤。
  • Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors
    申请人:Boys Mark Laurence
    公开号:US08841455B2
    公开(公告)日:2014-09-23
    Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.
    公式(I)的化合物及其药学上可接受的盐,其中R1、R2、R3、R4和R5的含义如说明书所述,是cFMS的抑制剂,并可用于治疗与骨相关的疾病、癌症、自身免疫性疾病、炎症性疾病、心血管疾病和疼痛。
  • SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    申请人:ARRAY BIOPHARMA INC.
    公开号:US20160002232A1
    公开(公告)日:2016-01-07
    Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    一种在哺乳动物中用于治疗纤维化、骨相关疾病、癌症、自身免疫性疾病、炎症性疾病、心血管疾病、疼痛和烧伤的化合物。
  • Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
    申请人:ARRAY BIOPHARMA INC.
    公开号:US10669269B2
    公开(公告)日:2020-06-02
    Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    式 I 的化合物: 及其药学上可接受的盐,其中 R1、R2、R3、R4、R5 和 R6 具有说明书中给出的含义,是 cFMS 的抑制剂,可用于治疗哺乳动物的纤维化、骨相关疾病、癌症、自身免疫性疾病、炎症性疾病、心血管疾病、疼痛和烧伤。
查看更多